NVIDIA Clara

BioNeMo is an AI-powered drug discovery cloud service and framework built on NVIDIA NeMo Megatron for training and deploying large biomolecular transformer AI models at a supercomputing scale. The service includes pre-trained large language models (LLMs) and native support for common file formats for proteins, DNA, RNA, and chemistry, providing data loaders for SMILES for molecular structures and FASTA for amino acid and nucleotide sequences. The BioNeMo framework will also be available for download for running on your own infrastructure. ESM-1, based on Meta AI’s state-of-the-art ESM-1b, and ProtT5 are transformer-based protein language models that can be used to generate learned embeddings for tasks like protein structure and property prediction. OpenFold, a deep learning model for 3D structure prediction of novel protein sequences, will be available in BioNeMo service.

Using RNA sequencing (RNA-seq) data and Artificial Intelligence are both a necessity and an opportunity to develop therapeutics that target splicing errors. The use of machine learning enables us to discover new splicing errors and quickly design therapeutic compounds to correct them. SpliceCore is our dedicated AI platform for RNA therapeutics discovery. We developed this technology platform specifically for the analysis of RNA sequencing data. It can identify, test and validate hypothetical drug targets faster than traditional methods. At the heart of SpliceCore is our proprietary database of more than 5 million potential RNA splicing errors. It is the largest database of splicing errors in the world and it is used to test every RNA sequencing dataset that is input for analysis. Scalable cloud computing enables us to process massive amounts of RNA sequencing data efficiently, at higher speed and lower cost, exponentially accelerating therapeutic innovation.